Inflammatory Regulation Effect of NAC on COVID-19 Treatment

Pilot Double Blinded Randomized Placebo Controlled Multi Central Clinical Trial on Inflammatory Regulation Effect of NAC on COVID-19

Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.

Inclusion Criteria:

• Adult above 18 years of age
• Admitted to the hospital With confirmed COVID-19 by RT-PCR test
• On oxygen supplement

Exclusion Criteria:

• Active use of NAC
• Known NAC allergy
• In the opinion of the treating team, progression of death is imminent and inevitable within the next 24 hour, irrespective of provision treatment
• All patients enrolled in any other investigational drug studies in COVID-19.